MICSI-PET
Microstructure Imaging, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for MICSI-PET, a 510(k) submitted by Microstructure Imaging, Inc. of Brooklyn, New York, with a decision date of September 11, 2026 and receipt date of April 20, 2026. The submission is K261305, a traditional 510(k) reviewed by FDA rather than a third party, listed under regulation 892.1200 with classification product code KPS and subsequent product code LLZ in the radiology specialty. SESE means clearance to market, not premarket approval.
The reviewed document describes MICSI-PET Super-Resolution as software as a medical device intended to enhance positron emission tomography brain images, and states the device is similar to its predicate with the same intended use environment and user. The public record does not identify the predicate device, the specific image-processing changes, or performance data supporting equivalence; those details remain in the underlying FDA documents. No clinical or diagnostic claims are established by this clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261305
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Microstructure Imaging, Inc.
- Product code
- KPS
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Tomography, Computed, Emission.
- Applicant
- Microstructure Imaging, Inc.
- Product code
- KPS
- FDA device class
- 2
FDA decision timeline
K261305 received
Application receipt date recorded by FDA.
K261305 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microstructure Imaging, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Brooklyn, NY
Sources and methodology
- Original FDA record: K261305
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records